Pathogenesis of Theiler's virus-induced demyelinating disease
Pathogenesis of Theiler's virus-induced demyelinating disease
批准号:
9093302
负责人:
RAYMOND Philip ROOS
金额:
$23.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-02-01 至 2018-01-31
关键词:
AcuteAntibodiesAutoimmune DiseasesBindingCD8B1 geneCardiomyopathiesCellsChronicDataDemyelinating DiseasesDemyelinationsDevelopmentDiabetes MellitusDiseaseEncephalomyelitisEquilibriumEventExperimental Autoimmune EncephalomyelitisExperimental ModelsFailureGenetic TranscriptionGranulocyte-Macrophage Colony-Stimulating FactorHealthHistocompatibility Antigens Class IIIRF3 geneImmuneImmune systemImmunologic FactorsImmunophenotypingInfectionInflammationInflammatoryInterferon-betaInterferonsInterleukin-10Interleukin-12Interleukin-17LeadMediatingMemoryModelingMultiple SclerosisMusNeuraxisPathogenesisPathologyPathway interactionsProductionProteinsRegulatory T-LymphocyteResearch PersonnelRoleSJL MouseSignal TransductionSiteSubgroupT-LymphocyteTMEVTh1 CellsViral GenomeVirusVirus Diseasescytokinedisease phenotypeinterleukin-23macrophagemembermutantnovel therapeuticspathogenpreventpromoterresponsetranscription factorvirus-induced demyelination
中文摘要
描述(由申请人提供):泰勒氏小鼠脑脊髓炎病毒(TMEV)DA株引起TMEV诱导的脱髓鞘疾病(TMEV-IDD),作为多发性硬化症(MS)的实验模型:这两种疾病都有相似的免疫介导的脱髓鞘病理。相比之下,TMEV的GDVII株可引起致命性脑脊髓炎,但没有脱髓鞘或病毒持久性。DA L和GDVII L蛋白都能抑制干扰素-β转录,但它们在IRF-3途径中的不同位置起作用。大L,因此DA病毒感染,阻断了irf-3的激活,而gdvii L,因此gdvii病毒感染(以及一种名为DALGDvii的突变病毒的感染,其中DA L被gdvii L取代),激活了irf-3,但阻断了irf-3与干扰素-β启动子的结合。值得注意的是,激活的IRF-3对IL-27的合成至关重要,IL-27抑制Th17细胞;减少CD4+记忆细胞分泌IL-17;对分泌IL-10的TR1细胞的分化很重要;TR1细胞是一种调节性T细胞,可以化解炎症并恢复耐受;负调控T细胞中粒细胞-巨噬细胞集落刺激因子(GM-CSF)的表达,这在介导实验性变态反应性脑脊髓炎(EAE)中起重要作用。激活的IRF-3还干扰IL-12和IL-23的亚基IL-12p40的产生,阻止幼稚T细胞极化为促炎Th1细胞(由IL-12诱导)和Th17细胞(由IL-23诱导)。在目前的建议中,我们假设IRF-3的激活或失败(以及IL-27/Th17的平衡)在TMEV引起的脱髓鞘以及(部分)确定TMEV两个亚型的疾病表型中是重要的。在感染各种病原体后,由于不能激活β-3而导致的干扰素-IRF反应的拮抗作用,这可能是在感染这些病原体后发生MS和/或MS攻击(或另一种自身免疫性疾病)的原因。更好地了解TMEV-IDD先天免疫系统的这些活动可能会阐明其发病机制,并为MS开辟新的治疗方向。
英文摘要
DESCRIPTION (provided by applicant): DA strain of Theiler's murine encephalomyelitis virus (TMEV) causes TMEV-induced demyelinating disease (TMEV-IDD), which serves as an experimental model of multiple sclerosis (MS): both diseases have similar immune-mediated demyelinating pathology. In contrast, GDVII strain of TMEV causes a fatal encephalomyelitis without demyelination or virus persistence. Both DA L and GDVII L protein block IFN-β transcription, however, they do so at different sites in the IRF-3 pathway. DA L, and therefore DA virus infection, blocks the activation of IRF-3, while GDVII L, and therefore GDVII virus infection (as well as infection by a mutant virus called DALGDVII, in which DA L is replaced by GDVII L), activates IRF-3, but blocks the binding of IRF-3 to the IFN-β promoter. Of note, activated IRF-3: is critical for IL-27 synthesis, which inhibits Th17 cells; decreases IL-17 secretion by CD4+ memory cells; is important in the differentiation of IL-10- secreting Tr1 cells, a regulatory T cell that can resolve inflammation and restore tolerance; negatively regulates granulocyte-macrophage-colony stimulating factor (GM-CSF) expression in T cells, which is important in mediating experimental allergic encephalomyelitis (EAE). Activated IRF-3 also interferes with production of IL- 12p40, a subunit of IL-12 and IL-23, preventing polarization of naïve T cells into proinflammatory Th1 cells (induced by IL-12) and Th17 cells (induced by IL-23). In the present proposal, we hypothesize that the activation or the failure of activation of IRF-3 (and the balance of IL-27/Th17) is important in the demyelination induced by TMEV, and in (partly) determining the two TMEV subgroup disease phenotypes. Antagonism of the IFN-β response because of a failure to activate IRF-3 may occur following infections with varied pathogens, and this may be the reason that the initiation of MS and/or an MS attack (or of another autoimmune disease) occurs after infection with these pathogens. A better understanding of these activities of the innate immune system in TMEV-IDD may clarify its pathogenesis and open up new therapeutic directions in MS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Guanabenz in the treatment of mutant SOD1 ALS mice
-
批准号:8442820
-
项目类别:
-
资助金额:$18.82万
-
财政年份:2012
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Guanabenz in the treatment of mutant SOD1 ALS mice
-
批准号:8280775
-
项目类别:
-
资助金额:$23.4万
-
财政年份:2012
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Single chain Fragments of variable regions in the treatment of Familial ALS
-
批准号:7904720
-
项目类别:
-
资助金额:$24.88万
-
财政年份:2010
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Single chain Fragments of variable regions in the treatment of Familial ALS
-
批准号:8049184
-
项目类别:
-
资助金额:$19.56万
-
财政年份:2010
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
-
批准号:8238678
-
项目类别:
-
资助金额:$5.74万
-
财政年份:2009
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
-
批准号:8036079
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
-
批准号:7779486
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
-
批准号:8435565
-
项目类别:
-
资助金额:$6.16万
-
财政年份:2009
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
-
批准号:8233407
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
-
批准号:8574844
-
项目类别:
-
资助金额:$0.49万
-
财政年份:2009
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
-
批准号:8436242
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Inducible Site-specific Expression of Mutant SOD1
-
批准号:6818358
-
项目类别:
-
资助金额:$21.16万
-
财政年份:2004
-
负责人:RAYMOND Philip ROOS
-
依托单位:
Inducible Site-specific Expression of Mutant SOD1
-
批准号:6884832
-
项目类别:
-
资助金额:$17.63万
-
财政年份:2004
-
负责人:RAYMOND Philip ROOS
-
依托单位:
CORE--SCIENTIFIC/CLINICAL
-
批准号:6598867
-
项目类别:
-
资助金额:$7.35万
-
财政年份:2002
-
负责人:RAYMOND Philip ROOS
-
依托单位:
NEURODEGENERATION AND NEUROPROTECTION IN MND
-
批准号:6598864
-
项目类别:
-
资助金额:$7.35万
-
财政年份:2002
-
负责人:RAYMOND Philip ROOS
-
依托单位:
NEURODEGENERATION AND NEUROPROTECTION IN MND
-
批准号:6495772
-
项目类别:
-
资助金额:$7.35万
-
财政年份:2001
-
负责人:RAYMOND Philip ROOS
-
依托单位:
CORE--SCIENTIFIC/CLINICAL
-
批准号:6459044
-
项目类别:
-
资助金额:$29.31万
-
财政年份:2001
-
负责人:RAYMOND Philip ROOS
-
依托单位:
NEURODEGENERATION AND NEUROPROTECTION IN MND
-
批准号:6459041
-
项目类别:
-
资助金额:$29.31万
-
财政年份:2001
-
负责人:RAYMOND Philip ROOS
-
依托单位:
CORE--SCIENTIFIC/CLINICAL
-
批准号:6495775
-
项目类别:
-
资助金额:$7.35万
-
财政年份:2001
-
负责人:RAYMOND Philip ROOS
-
依托单位:
CORE--SCIENTIFIC/CLINICAL
-
批准号:6326014
-
项目类别:
-
资助金额:$22.98万
-
财政年份:2000
-
负责人:RAYMOND Philip ROOS
-
依托单位:
海外基金